Alginic Acid Ameliorates Osteoarthritis Through FOXO3a ‐Dependent Regulation of the EREG – MAPK Signaling Axis
Osteoarthritis (OA) lacks effective disease-modifying therapies. This study evaluated the therapeutic potential of alginic acid (AA), which was identified through a FOXO3a-oriented virtual screening strategy, and investigated its downstream regulatory mechanism with a focus on the EREG-MAPK signaling axis. AA was prioritized through structure-based virtual screening against FOXO3a followed by functional secondary screening. In vitro, IL-1β-stimulated human OA chondrocytes were treated with AA and assessed for extracellular matrix metabolism, inflammation, apoptosis, and MAPK pathway activity. FOXO3a knockdown and EREG-overexpression rescue experiments were performed to evaluate the functional roles of FOXO3a and EREG. In vivo, DMM-induced OA rats received intra-articular AA treatment, followed by assessment of pain behavior, cartilage pathology, and matrix preservation. Transcriptomic analysis was used to identify AA-responsive genes and signaling pathways under OA-like inflammatory conditions. AA promoted cartilage matrix synthesis, reduced matrix degradation and inflammatory responses, and attenuated chondrocyte apoptosis in vitro. In DMM-induced OA rats, AA alleviated pain hypersensitivity and reduced cartilage degeneration. Transcriptomic and subsequent validation analyses identified EREG and MAPK signaling as AA-responsive components. AA reduced EREG expression and MAPK phosphorylation. Importantly, FOXO3a knockdown markedly attenuated the effects of AA on EREG expression, p38 MAPK activation, and cartilage matrix homeostasis, supporting a functional requirement for FOXO3a in AA-mediated chondroprotection. Conversely, EREG overexpression partially counteracted the protective effects of AA. AA exerts chondroprotective effects in experimental OA and appears to act, at least in part, through FOXO3a-dependent suppression of EREG-MAPK signaling. These findings strengthen the mechanistic basis for AA as a potential OA therapeutic candidate while supporting further investigation of the FOXO3a-EREG-MAPK regulatory axis.
Authors
- Ruizhou Liu (ORCID: https://orcid.org/0000-0001-6004-9445)
- Xiaolei Li (ORCID: https://orcid.org/0000-0001-6247-1148)
- Hui Chen (ORCID: https://orcid.org/0000-0002-8052-0051)
- Longchi Chen
- Shihan Wang
- Tianyu Zhang
- PAN Bingqi (ORCID: https://orcid.org/0009-0002-4339-9421)
Institutions
- Xuzhou Medical College (CN)
- Northern Jiangsu People's Hospital (CN)
- Second Affiliated Hospital of Xuzhou Medical College (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Yangzhou University (CN)
Publication Details
- Journal
- Phytotherapy Research
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1002/ptr.70501
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- YangZhou Science and Technology Bureau